1832 Asset Management L.P. Repligen Corp Transaction History

1832 Asset Management L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$160.42 - $256.21 $76.4 Million - $122 Million	476,200 Added 687.16%	545,500 $102 Million
Q2 2022 Aug 15, 2022	SELL	$140.68 - $188.02 $52.5 Million - $70.2 Million	-373,200 Reduced 84.34%	69,300 $11.3 Million
Q1 2022 May 16, 2022	SELL	$161.19 - $257.96 $36.9 Million - $59 Million	-228,700 Reduced 34.07%	442,500 $82.2 Million
Q4 2021 Feb 15, 2022	SELL	$247.59 - $304.47 $14.6 Million - $17.9 Million	-58,800 Reduced 8.05%	671,200 $174 Million
Q4 2020 Feb 16, 2021	BUY	$148.08 - $206.57 $503,472 - $702,338	3,400 Added 0.47%	730,000 $136 Million
Q2 2020 Aug 14, 2020	SELL	$94.33 - $140.48 $169,794 - $252,863	-1,800 Reduced 0.25%	726,600 $85.1 Million
Q4 2019 Feb 14, 2020	SELL	$73.84 - $93.08 $6.73 Million - $8.49 Million	-91,200 Reduced 11.13%	728,400 $65.9 Million
Q3 2019 Nov 14, 2019	BUY	$76.65 - $95.51 $10.7 Million - $13.3 Million	139,100 Added 20.44%	819,600 $61.4 Million
Q2 2019 Aug 14, 2019	BUY	$54.2 - $85.95 $36.9 Million - $58.5 Million	680,500 New	680,500 $55.8 Million

488

54.2M

341K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.02B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on 1832 Asset Management L.P. with notifications on news.